Premium
P4‐540: CSF PTAU‐217 PERFORMS BETTER THAN PTAU‐181 IN DETECTING ABNORMAL RETENTION OF 18 F‐FLORTAUCIPIR AND DISCRIMINATING ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS
Author(s) -
Janelidze Shorena,
Smith Ruben,
Dage Jeffrey,
Proctor Nicholas,
Chai Xiyun,
Airey David C.,
Hansson Oskar
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.08.087
Subject(s) - cerebrospinal fluid , pathology , cognitive impairment , biomarker , threonine , dementia , positron emission tomography , tau protein , alzheimer's disease , neuroscience , chemistry , psychology , disease , medicine , phosphorylation , biochemistry , serine
P4-540 CSF PTAU-217 PERFORMS BETTER THAN PTAU-181 IN DETECTING ABNORMAL RETENTION OF F-FLORTAUCIPIR AND DISCRIMINATING ALZHEIMER’S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS Shorena Janelidze, Ruben Smith, Jeffrey Dage, Nicholas Proctor, Xiyun Chai, David C. Airey, Oskar Hansson, Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm€o, Sweden; Clinical Memory Research Unit, Lund University, Malm€o, Sweden; Eli Lilly and Company, Indianapolis, IN, USA; Sk ane University Hospital, Lund, Sweden. Contact e-mail: Shorena.janelidze@med.lu.se